| 产品名称： | 重组人RANK/TNFRSF11A |
|---|---|
| 产品又名： | CD265细胞因子, CD265细胞因子 |
| 英文名称： | CD265; ODFR; TNFRSF11A; TRANCE R; CD265; CD265 antigen; FEO; ODFROSTS; OFE; OPTB7; PDB2; RANK1; Receptor activator of NF-KB; receptor activator of nuclear factor-kappa B; TRANCER; tumor necrosis factor receptor superfamily member 11A |
| 产品说明: | NF-kappa-B重组人受体激活子是由我们的哺乳动物表达系统产生的，编码Ile30-Pro212的靶基因在C-端有6His标记表达。 |
| 背景说明: | 核因子受体激活因子B(κB，RANK)又称CD 265、TNFRSF11A或TNFRSF11A，是肿瘤坏死因子受体(TNFR)分子超家族的成员。RANK是RANKL的受体，是调节破骨细胞分化和活化的RANK/RANKL/OPG信号通路的一部分。它在骨重塑和修复、免疫细胞功能、淋巴结发育、热调节和乳腺发育等方面发挥着重要作用。RANK在骨骼肌、胸腺、肝脏、结肠、小肠、肾上腺、破骨细胞、乳腺上皮细胞、前列腺、血管细胞和胰腺中均有表达。 |
| 级别： | AR |
| 品牌： | ELITE-MEDIA |
| 产品目录号： | Q9Y6Q6 |
| 产品规格： | 10ug、50ug |
| 产品外观： | 乳白色均一粉末。 |
| 制剂： | 冻干从0.2μm过滤的PBS溶液中，pH值为7.4。 |
| 保存条件： |
冻干蛋白应保存在<-20°C，室温下保存3周。
重组蛋白溶液可在4-7℃保存2~7d。
重组样品在<-20℃温度下稳定3个月。
|
| 质量控制: |
纯度：通过减少SDS-PAGE而确定的95%以上。
内毒素：LAL法测定小于0.1ng/g(1 Eu/？g)。
|
| 注意事项： | 避免呼入和皮肤接触。 |
| 文献引用： |
Mouse Embryonic Fibroblast Adipogenic Potential: A Comprehensive Transcriptome Analysis. Al-Sayegh, Ali, Jamal, ElGindi, Chanyong, Al-Awadi, Abu-Farha, Adipocyte(2021 12)
Clinical and inflammatory features based machine learning model for fatal risk prediction of hospitalized COVID-19 patients: results from a retrospective cohort study. Guan, Zhang, Fu, Li, Yuan, Zhu, Peng, Guo, Lu, Ann Med(2021 12)
Admission hyperglycaemia as a predictor of mortality in patients hospitalized with COVID-19 regardless of diabetes status: data from the Spanish SEMI-COVID-19 Registry. Carrasco-Sánchez, López-Carmona, Martínez-Marcos, Pérez-Belmonte, Hidalgo-Jiménez, Buonaiuto, Suárez Fernández, Freire Castro, Luordo, Pesqueira Fontan, Blázquez Encinar, Magallanes Gamboa, de la Peña Fernández, Torres Peña, Fernández Solà, Napal Lecumberri, Amorós Martínez, Guisado Espartero, Jorge Ripper, Gómez Méndez, Vicente López, Román Bernal, Rojano Rivero, Ramos Rincón, Gómez Huelgas, SEMI-COVID-19 Network, Ann Med(2021 12)
Identification of TYR, TYRP1, DCT and LARP7 as related biomarkers and immune infiltration characteristics of vitiligo via comprehensive strategies. Zhang, Yu, Guo, Zou, Chen, Zhou, Chen, Li, Gao, Wu, Bioengineered(2021 Dec)
The effect of the detection of minimal residual disease for the prognosis and the choice of post-remission therapy of intermediate-risk acute myeloid leukemia without FLT3-ITD, NPM1 and biallelic CEBPA mutations. Zheng, Hu, Guan, Peng, Wang, Hematology(2021 Dec)
|
买家导航
CD265细胞因子产品基本信息
CD265细胞因子产品说明书pdf版和相关资料下载
CD265细胞因子产品应用举例
- 上一篇：IFN alpha2细胞因子
- 下一篇：OPG细胞因子
